YH 23537

Drug Profile

YH 23537

Alternative Names: YH23537

Latest Information Update: 09 May 2016

Price : $50

At a glance

  • Originator Yuhan
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteoarthritis; Periodontitis

Most Recent Events

  • 28 Apr 2016 Yuhan Corporation plans a phase II trial for Osteoarthritis in South Korea (PO) (NCT02759198)
  • 01 Apr 2016 Phase-II clinical trials in Osteoarthritis (Osteoarthritis of knee) in South Korea (PO) (NCT02759198)
  • 14 Jan 2016 Phase-II clinical trials in Periodontitis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top